Taladegib is under clinical development by F. Hoffmann-La Roche and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Taladegib’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Taladegib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Taladegib overview

Taladegib (LY-2940680) is under development for the treatment of  advanced cancers including epithelial ovarian, fallopian tube or primary peritoneal cancer and adenocarcinoma of the esophagus or gastroesophageal junction, idiopathic pulmonary fibrosis (IPF) and advanced solid tumors harboring PTCH1 loss of function mutations. The drug candidate targets smoothened (SMO) receptor. The drug candidate is administered through oral route. It was also under development for small cell lung cancer, recurrent or refractory rhabdomyosarcoma, refractory medulloblastoma and as a topical formulation for superficial and nodular basal cell carcinoma.

F. Hoffmann-La Roche overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

Quick View Taladegib LOA Data

Report Segments
  • Innovator
Drug Name
  • Taladegib
Administration Pathway
  • Oral
  • Topical
Therapeutic Areas
  • Oncology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.